



PSORIASIS

MAINTENANCE OF PASI 90 RESPONSE WITH GUSELKUMAB THROUGH 3-YEARS (WEEK 156) AMONG WEEK 28 PASI 90 RESPONDERS IN THE VOYAGE 1 STUDY

Kb Gordon⁽¹⁾ - *P Foley*⁽²⁾ - *C Leonardi*⁽³⁾ - *I Landells*⁽⁴⁾ - *M Song*⁽⁵⁾ - *S Fakharzadeh*⁽⁶⁾ - *Y-k Shen*⁽⁷⁾ - *S Li*⁽⁷⁾ - *R Langley*⁽⁸⁾ - *K Reich*⁽⁹⁾

Medical College Of Wisconsin, Dermatology, Milwaukee, United States⁽¹⁾ - *University Of Melbourne, St. Vincent's Hospital, , Melbourne And Skin & Cancer Foundation Inc., Dermatology, Carlton, Australia*⁽²⁾ - *Central Dermatology, Dermatology, St. Louis, United States*⁽³⁾ - *Nexus Clinical Research, Dermatology, St. John's, Canada*⁽⁴⁾ - *Janssen Research & Development, Llc, Immunology, Spring House, United States*⁽⁵⁾ - *Janssen Scientific Affairs, Llc, Medical Affairs, Horsham, United States*⁽⁶⁾ - *Janssen Research & Development, Llc, Clinical Biostatistics, Spring House, United States*⁽⁷⁾ - *Dalhousie University, Dermatology, Halifax, Canada*⁽⁸⁾ - *Dermatologikum Berlin And Sciderm Research Institute, Dermatology, Hamburg, Germany*⁽⁹⁾

Intro/Objective: To evaluate maintenance of response to guselkumab (GUS), a fully human monoclonal antibody that selectively binds and blocks interleukin-23, in patients with moderate-severe plaque psoriasis (PsO) who achieved $\geq 90\%$ improvement in their Psoriasis Area and Severity Index score (PASI 90) response at Wk28 compared to baseline.

Materials/Methods: In VOYAGE 1 adults (N=837) were randomized to 3 treatment groups in a 2:1:2 ratio: 1) GUS 100mg at Wks0, 4, 12 then q8w; 2) PBO at Wks0, 4, and 12 followed by GUS 100mg at Wks16 and 20, then q8w; or 3) adalimumab (ADA) 80mg at Wk0, 40 mg at Wk1, and 40mg q2w through Wk47. The open-label phase of the study began after Wk48; GUS and PBO→GUS patients continued to receive GUS 100mg q8w, while ADA patients switched to GUS 100mg q8w at Wk52 and continued GUS treatment through Wk148. This post-hoc analysis assessed long-term maintenance of response through Wk156 among patients who achieved a PASI90 response at Wk28. Data for patients originally randomized to GUS and PBO→GUS patients were combined. The analysis was performed using observed data after applying treatment failure rules.

Results: Among Wk28 PASI90 responders in GUS/PBO→GUS group (n=365), 91.0%, 90.0%, and 87.3% maintained a PASI90 response at Wks52, 100, and 156, respectively, with continuous GUS treatment. More than 98% of patients maintained a PASI75 response at each of these time points. Among Wk28 PASI90 responders in the





ADA group, 83.9% had a PASI90 response at Wk48. After switching to GUS at Wk52, a PASI90 response was maintained by 86.2% and 87.7% of patients at Wks100 and 156, respectively. Treatment with GUS was well-tolerated through Wk156.

Conclusions: In VOYAGE 1, among patients who achieved a PASI90 response at Wk28, durable maintenance of PASI90 response was observed through Wk156 (3 years) with continuous GUS treatment.

